Management of Delayed Elimination of High-Dose Methotrexate in Community Oncology Practices Can Mitigate Its Effect on Length of Hospital Stay, Treatment Dose-Density, Acute Kidney Injury, Dialysis, and Death

MLA

Sfondouris John, et al. “Management of Delayed Elimination of High-Dose Methotrexate in Community Oncology Practices Can Mitigate Its Effect on Length of Hospital Stay, Treatment Dose-Density, Acute Kidney Injury, Dialysis, and Death.” Blood, vol. 134, Nov. 2019, p. 5889. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........67bfe5af04d33db4139b09236628c74f&authtype=sso&custid=ns315887.

APA

Sfondouris John, McKeon Tad Harry, Scott C. Howard, Suresh Marada, & Nicholas Napier. (2019). Management of Delayed Elimination of High-Dose Methotrexate in Community Oncology Practices Can Mitigate Its Effect on Length of Hospital Stay, Treatment Dose-Density, Acute Kidney Injury, Dialysis, and Death. Blood, 134, 5889.

Chicago

Sfondouris John, McKeon Tad Harry, Scott C. Howard, Suresh Marada, and Nicholas Napier. 2019. “Management of Delayed Elimination of High-Dose Methotrexate in Community Oncology Practices Can Mitigate Its Effect on Length of Hospital Stay, Treatment Dose-Density, Acute Kidney Injury, Dialysis, and Death.” Blood 134 (November): 5889. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........67bfe5af04d33db4139b09236628c74f&authtype=sso&custid=ns315887.